FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck Purchases 5,000 Shares of Stock

FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, with a total value of $23,750.00. Following the completion of the transaction, the chief financial officer directly owned 181,610 shares in the company, valued at approximately $862,647.50. The trade was a 2.83% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

FocalTherics Stock Performance

Shares of FOCL opened at $4.76 on Monday. The firm has a 50-day moving average of $5.39. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The stock has a market cap of $178.40 million, a price-to-earnings ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The company had revenue of $13.20 million for the quarter. Equities research analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on FOCL shares. Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday. Mizuho set a $15.00 price target on FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Piper Sandler restated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of FocalTherics in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Institutional Trading of FocalTherics

Large investors have recently made changes to their positions in the company. SmartHarvest Portfolios LLC acquired a new stake in FocalTherics in the first quarter valued at approximately $38,000. Lido Advisors LLC purchased a new stake in shares of FocalTherics during the 1st quarter worth $40,000. Kovack Advisors Inc. purchased a new stake in shares of FocalTherics during the 4th quarter worth $53,000. Rock Springs Capital Management LP grew its stake in shares of FocalTherics by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock worth $4,233,000 after purchasing an additional 16,500 shares in the last quarter. Finally, Leonteq Securities AG acquired a new position in shares of FocalTherics during the fourth quarter worth $313,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.